Danaher Co. (NYSE:DHR) Shares Sold by Integrated Investment Consultants LLC

Integrated Investment Consultants LLC decreased its stake in shares of Danaher Co. (NYSE:DHR) by 14.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,383 shares of the conglomerate’s stock after selling 228 shares during the quarter. Integrated Investment Consultants LLC’s holdings in Danaher were worth $317,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in DHR. Decker Retirement Planning Inc. purchased a new stake in Danaher during the fourth quarter worth about $31,000. Teachers Insurance & Annuity Association of America purchased a new position in Danaher in the third quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. purchased a new position in Danaher in the third quarter valued at approximately $40,000. FSA Wealth Management LLC purchased a new position in Danaher in the third quarter valued at approximately $50,000. Finally, Darwin Wealth Management LLC purchased a new position in Danaher in the third quarter valued at approximately $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on DHR. Evercore ISI increased their price objective on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Raymond James dropped their price objective on Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. TD Cowen lifted their price objective on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. Finally, Guggenheim started coverage on Danaher in a report on Thursday, December 19th. They issued a “buy” rating and a $275.00 price target for the company. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $286.80.

Danaher Stock Down 1.4 %

NYSE:DHR opened at $238.41 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The stock has a market cap of $172.20 billion, a price-to-earnings ratio of 45.50, a PEG ratio of 4.23 and a beta of 0.83. The stock has a 50-day moving average price of $234.85 and a two-hundred day moving average price of $253.32. Danaher Co. has a 1 year low of $222.53 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. Danaher’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.02 earnings per share. As a group, equities analysts expect that Danaher Co. will post 7.49 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio is currently 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.